These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 4001740)

  • 1. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection.
    Horstmann DM; Schluederberg A; Emmons JE; Evans BK; Randolph MF; Andiman WA
    Rev Infect Dis; 1985; 7 Suppl 1():S80-5. PubMed ID: 4001740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing and hemagglutination-inhibiting antibodies to rubella virus as indicators of protective immunity in vaccinees and naturally immune individuals.
    Schluederberg A; Horstmann DM; Andiman WA; Randolph MF
    J Infect Dis; 1978 Dec; 138(6):877-83. PubMed ID: 105058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the latex agglutination test with the hemagglutination inhibition test, enzyme-linked immunosorbent assay, and neutralization test for detection of antibodies to rubella virus.
    Meegan JM; Evans BK; Horstmann DM
    J Clin Microbiol; 1982 Oct; 16(4):644-9. PubMed ID: 7153314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenge with rubella virus after loss of detectable vaccine-induced antibody.
    Schiff GM; Young BC; Stefanovic' GM; Stamler EF; Knowlton DR; Grundy BJ; Dorsett PH
    Rev Infect Dis; 1985; 7 Suppl 1():S157-63. PubMed ID: 4001723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low level rubella immunity detected by ELISA and specific lymphocyte transformation.
    Buimovici-Klein E; O'Beirne AJ; Millian SJ; Cooper LZ
    Arch Virol; 1980; 66(4):321-7. PubMed ID: 7447708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological response to rubella revaccination.
    Serdula MK; Halstead SB; Wiebenga NH; Herrmann KL
    JAMA; 1984 Apr; 251(15):1974-7. PubMed ID: 6700099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of immunity after rubella vaccination: a long-term study in Switzerland.
    Just M; Just V; Berger R; Burkhardt F; Schilt U
    Rev Infect Dis; 1985; 7 Suppl 1():S91-4. PubMed ID: 4001742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of rubella virus-specific antibody responses by using a new synthetic peptide-based enzyme-linked immunosorbent assay.
    Mitchell LA; Zhang T; Ho M; Décarie D; Tingle AJ; Zrein M; Lacroix M
    J Clin Microbiol; 1992 Jul; 30(7):1841-7. PubMed ID: 1629342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further evaluation of the optimum age for rubella vaccine administration.
    Wilkins J; Wehrle PF
    Am J Dis Child; 1979 Dec; 133(12):1237-9. PubMed ID: 517472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latex-agglutination test for rubella antibody: validity of positive results assessed by response to immunization and comparison with other tests.
    Storch GA; Myers N
    J Infect Dis; 1984 Mar; 149(3):459-64. PubMed ID: 6371155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlling rubella: problems and perspectives.
    Horstmann DM
    Ann Intern Med; 1975 Sep; 83(3):412-7. PubMed ID: 1180441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to intranasal challenge with Rubella virus two years after vaccination: comparison of three vaccines.
    Grillner L
    J Infect Dis; 1976 Jun; 133(6):637-41. PubMed ID: 932491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the reactogenicity and immunogenicity of the BRD-2 and RA27/3 live attenuated rubella vaccines.
    Wang SS; Han YR; Su WN; Chen J; Zhao K
    Vaccine; 1984 Dec; 2(4):277-80. PubMed ID: 6531968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Wistar RA27/3 rubella virus vaccine in children.
    Balfour HH; Balfour CL; Edelman CK; Rierson PA
    Am J Dis Child; 1976 Oct; 130(10):1089-91. PubMed ID: 973611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive neutralization test for rubella antibody.
    Sato H; Albrecht P; Krugman S; Ennis FA
    J Clin Microbiol; 1979 Feb; 9(2):259-65. PubMed ID: 107192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of enzyme-linked immunosorbent assay, hemagglutination inhibition, and passive latex agglutination for determination of rubella immune status.
    Steece RS; Talley MS; Skeels MR; Lanier GA
    J Clin Microbiol; 1985 Jan; 21(1):140-2. PubMed ID: 3968201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of enzyme immunoassays and the latex agglutination test to measure the temporal appearance of immunoglobulin G and M antibodies after natural infection or immunization with rubella virus.
    Meegan JM; Evans BK; Horstmann DM
    J Clin Microbiol; 1983 Sep; 18(3):745-8. PubMed ID: 6630452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of rubella antibodies after vaccination: detection after experimental challenge.
    Banatvala JE; Best JM; O'Shea S; Dudgeon JA
    Rev Infect Dis; 1985; 7 Suppl 1():S86-90. PubMed ID: 4001741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of young women vaccinated against rubella virus for 10 years in Taiwan.
    Lin DB; Kao CL; Lee CY
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):707-14. PubMed ID: 9253871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.